AstraZeneca's Evusheld nabs its first global nod as a COVID treatment

AstraZeneca’s COVID-19 antibody Evusheld nabbed its first global nod as a coronavirus treatment. Already authorized in many places to prevent infection prior to exposure, the drug is set to reach a broader set of patients in Japan.